Functional drug assays performed in CRC08 PDOs corroborated the vulnerability of irinotecan-resistant cancer cells to the attenuation of HDAC activity, suggesting that HDAC inhibition could be a viable treatment strategy for metCRC patients who progressed on irinotecan-based combination therapies. This evidence concerns the gene HDAC9 and cancer.